The marketing authorization application (MAA) was filed with Swissmedic by Sucampo Pharmaceuticals’s branch office in Basel, Switzerland. The submission is part of the ongoing development of Amitiza 24mcg
The international, double-blind, placebo-controlled safety and efficacy study of oral Dimebon is known as the Connection study. The Connection study will enroll approximately 525 patients with mild-to-moderate Alzheimer’s
Avid’s 18F-AV-45 is used with positron emission tomography (PET) to allow visualization of the amyloid plaque deposits in the brain that are characteristic of Alzheimer’s disease. This US
The combined company will have an expanded portfolio of clinical development programs in oncology, amyotrophic lateral sclerosis, stroke recovery and diabetic foot ulcers. In addition, the combined company
The acquisition was completed with cash, and the practice is expected to contribute to Pediatrix’s earnings per share immediately. With the acquisition of Pediatric Cardiology Associates, Pediatrix’s national
The new product, which rounds out OrbusNeich’s balloon catheter portfolio, is designed for use in focused force angioplasty, a technique in which the force resulting from balloon inflation
The boards of directors of both companies unanimously approved the transaction in which Hologic is to acquire 100% of Third Wave’s stock in a cash tender offer to
Under the terms of the agreement, Allergan will pay approximately $150 million for all assets relating to Aczone gel 5% upon closing, which is expected to occur in
Arpeggio, performed in 60 centers, throughout 12 countries, was a double-blind, randomized, parallel-group, fixed-dose, two-arm, controlled trial (rimonabant 20mg/once daily versus control). Patients had type 2 diabetes treated
Alexza said that the novel, non-invasive nature and rapid pharmacokinetic properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a viable
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.